<img alt="dcsimg" id="dcsimg" width="1" height="1" src="//statse.webtrendslive.com/dcswdijls000000kv5t913ro9_6z9m/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=10.4.12&amp;dcssip=www.aranesp.com"/>
X

Indication

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia... read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.

Limitations of Use

  • Aranesp® has not been shown to improve quality of life, fatigue, or patient well-being.
  • Aranesp® is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
› Email› Print

Isn’t it nice to know you have both?

Multiple dosing options

with QW and Q2W intervals1

AN ABILITY TO INTERVENE

when patients experience frequent changes to their Hb levels 1,2

Abbreviations and References:
QW = once weekly; Q2W = once every 2 weeks; Hb = hemoglobin.
References: 1. Aranesp® (darbepoetin alfa) prescribing information, Amgen. 2. Khan I, Krishnan M, Kothawala A, Ashfaq A. Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis. BMC Nephrol. 2011;12:22.